Immunocan, the joint institute Fudan University Shanghai Cancer Center – Institut Mérieux laboratory (FDUSCC-IM), created in May 2010 and ended in 2017, was conducting ambitious scientific research projects on oncology in China. Its 2 founding partners, Fudan University Shanghai Cancer Center (China) and Transgene (part of Institut Mérieux, France) wished to increase their translational medical research cooperation with European countries. In a first step, collaboration enlarged to an active partnership with Danish, Italian and German teams, with the following objectives:

Research activities were held in China in collaboration with the new European partners, in order to enhance current research activities of the joint institute and to create durable links between Chinese and European teams.

Research was focused on immune phenotype as personalized medical biomarker for prognosis of Chinese cancer patients, and was extended to new types of cancer and biomarkers. These prognosis studies helped to guide clinical decision-making by facilitating the selection of appropriate treatment options.

» Immunocan presentation slide

Partners and Sponsors

• Founding members: Transgenefduscc
• Partners: Medical Hannover Schoolintucph
• Sponsors: eufp7


In addition to its partners and sponsors (on the right), the joint institute Fudan University Shanghai Cancer Center – Institut Mérieux laboratory (FDUSCC-IM) also benefits from the contribution of its collaborators:

blpcen   abv   cgfl

inserm   ircan   lyonbiopole

Immunocan network

		Founding members and partners:

			Fudan University Shanghai Cancer Center (FDUSCC) (Shanghai, China (People's Republic of))
			University of Copenhagen (UCPH) (Copenhagen, Denmark)
			Transgene (TNG) (Illkirch, France)
			Hannover Medical School (MHH) (Hannover, Germany)
			Fondazione IRCCS Istituto Nazionale Dei Tumori (INT) (Milan, Italy)


			Biobank LPCE - Hôpital Pasteur (BLPCEN) (Nice, France)
			Alsace BioValley (ABV) (Illkirch, France)
			Centre Georges François Leclerc (CGFL) (Dijon, France)
			Institut national de la santé et de la recherche médicale (INSERM) (Paris, France)
			Institut de recherche sur le cancer et le vieillissement, Nice (IRCAN) (Nice, France)
			Lyonbiopôle (LBP) (Lyon, France)


Person in charge of scientific and technical/technological aspects:



The international cooperation program IMMUNOCAN has been divided into 5 work-packages addressing the needs for:

The first work-package aims at increasing knowledge exchanges between Europe and China in the field of cancer prognosis by:

The second work-package plans to create optimal conditions to host young and fellow researchers, enhancing the research capacity and the competence transfer to the joint institute by providing adequate and gender-balanced human resources as well as equipment to conduct beyond the state-of-the-art oncology research.

The third work-package focuses on the scientific activities resulting in an increased European involvement in the joint institute. In order to strengthen and expand the joint institute as a Euro-Chinese leading laboratory in cancer prognosis, current research directions will be pursued and new investigations will be jointly developed leaning on European partners’ expertises. Research activities will be organized around 6 topics, each being addressed by various partners of the project, according to their expertise field.

The fourth work-package intends to promote the joint institute as a leading Euro-Asian centre on Chinese cancer prognosis by:

The fifth work-package will be in charge of IMMUNOCAN coordination, management and administration, essential tasks in an international collaborative project.

News history